文献速递血液净化与透析肾血管病与高血压

透析中的血压管理:一项试点研究

BP in Dialysis: Results of a Pilot Study.
PubMed 文献 · J Am Soc Nephrol · 2017-12-06

该试点研究将126例接受血液透析的高血压患者随机分入强化降压组(透析前收缩压110-140 mmHg)或标准降压组(155-165 mmHg),主要评估可行性与安全性。中位随访365天,两组间收缩压平均差异为12.9 mmHg,强化组主要不良心血管事件、住院和血管通路血栓形成的发生率比分别为1.18、1.61和3.09,但研究样本小、持续时间短,无法得出确定性结论。

要点

  • 强化降压至透析前收缩压110-140 mmHg在血液透析患者中可行,但可能存在安全性信号。
  • 强化组与标准组间收缩压平均差异为12.9 mmHg,左心室质量变化相似。
  • 研究规模小、随访短,需开展全规模试验评估强化降压的潜在获益。

核心结论

  • 强化降压至透析前收缩压110-140 mmHg在血液透析患者中可行,但可能存在安全性信号,需全规模试验进一步评估。

研究设计与样本

  • 随机对照试点研究,纳入126例接受血液透析的高血压患者,随机分为强化降压组(透析前收缩压110-140 mmHg)或标准降压组(155-165 mmHg),中位随访365天。

主要发现

  • 强化组收缩压从基线160 mmHg降至4.5个月时的143 mmHg,标准组2周移动平均收缩压无显著变化。
  • 第4-12个月,两组间收缩压平均差异为12.9 mmHg。
  • 强化组与标准组主要不良心血管事件、住院和血管通路血栓形成的发生率比(95%CI)分别为1.18(0.40-3.33)、1.61(0.87-2.97)和3.09(0.96-8.78)。
  • 强化组和标准组左心室质量中位变化(95%CI)分别为-0.84(-17.1至10.0)g和1.4(-11.6至10.4)g。

临床怎么用

  • 对于血液透析高血压患者,强化降压至透析前收缩压110-140 mmHg可行,但需警惕潜在安全性信号,目前证据不足以支持常规推荐。

局限性

  • 研究样本量小(126例)且随访时间短(中位365天),无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal BP target for patients receiving hemodialysis is unknown. We randomized 126 hypertensive patients on hemodialysis to a standardized predialysis systolic BP of 110-140 mmHg (intensive arm) or 155-165 mmHg (standard arm). The primary objectives were to assess feasibility and safety and inform the design of a full-scale trial. A secondary objective was to assess changes in left ventricular mass. Median follow-up was 365 days. In the standard arm, the 2-week moving average systolic BP did not change significantly during the intervention period, but in the intensive arm, systolic BP decreased from 160 mmHg at baseline to 143 mmHg at 4.5 months. From months 4-12, the mean separation in systolic BP between arms was 12.9 mmHg. Four deaths occurred in the intensive arm and one death occurred in the standard arm. The incidence rate ratios for the intensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33), 1.61 (0.87 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vascular access thrombosis, respectively. The intensive and standard arms had similar median changes (95% confidence intervals) in left ventricular mass of -0.84 (-17.1 to 10.0) g and 1.4 (-11.6 to 10.4) g, respectively. Although we identified a possible safety signal, the small size and short duration of the trial prevent definitive conclusions. Considering the high risk for major adverse cardiovascular events in patients receiving hemodialysis, a full-scale trial is needed to assess potential benefits of intensive hypertension control in this population.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Miskulin DC, Gassman J, Schrader R, et al. BP in Dialysis: Results of a Pilot Study. J Am Soc Nephrol. 2017. PMID: 29212839. doi:10.1681/ASN.2017020135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。